STERISHEALTHCARE Products
Mumbai 08042755542 info@sterispharma.com
918209542042
Chat with us  

Chat with us on WhatsApp

×
Preview

This is your website preview.

Currently it only shows your basic business info. Start adding relevant business details such as description, images and products or services to gain your customers attention by using Boost 360 android app / iOS App / web portal.

STERISHEALTHCARE 573431969ec6680ff811d9bc Products https://www.sterisindia.com
Home Products R.S. IPRATROP 1.25
R.S. IPRATROP 1.25
R.S. IPRATROP 1.25
COD not available
ASTHMARANGE by Levosalbutamol & Ipratropium Bromide Respiratory Solution

R.S. IPRATROP 1.25

INR 282 INR 404
You Save: INR 122 (30.2%)
Check On
Share with
Check On
Share this on :

Description

Product details

R.S. IPRATROP 1.25 Levosalbutamol & Ipratropium Bromide Respiratory Solution "R.S. IPRATROP 1.25 is a dual-action respiratory solution combining Levosalbutamol and Ipratropium Bromide, tailored for effective relief in chronic obstructive pulmonary disease (COPD) and asthma. Levosalbutamol aids in relaxing the airway muscles for easier breathing, while Ipratropium reduces airway secretions. This combination works synergistically to improve airflow, alleviate symptoms, and enhance overall lung function, making it a vital treatment option for managing bronchospasm." For further information: Email: info@sterispharma.com / contact@sterispharma.com Call/WhatsApp: 7877551268, 7849827488 ORDER Now:

Other Products

Related Products

IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​ Product Overview IMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​ The medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​ Primary Uses IMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​ In gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​ Healthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​ Key Benefits One standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​ Tumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​ Additional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​ Potential Side Effects While generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​ Musculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​ Avoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​ Dosage and Administration Guidelines Swallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​ Renal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​ Precautions and Interactions Patients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​ Regular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​ Conclusion IMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.
View Details
Imatinib IP 400mg

INR1827

CONARIS T100 is a potent antifungal medication formulated with Terbinafine 250 mg and Itraconazole 100 mg. This combination tablet is designed to treat a wide range of fungal infections affecting the skin, nails, and other body parts. Terbinafine and Itraconazole work synergistically to eliminate fungi effectively by targeting their cell membranes and inhibiting growth, providing faster relief from symptoms such as itching, redness, scaling, and discomfort. Fungal infections are common in humid climates and among individuals with compromised immunity, and medications like CONARIS T100 are essential for managing stubborn and recurrent infections. This combination therapy is often prescribed by dermatologists and healthcare professionals for moderate to severe fungal conditions. Uses CONARIS T100 is used in the treatment of several fungal infections, including: Dermatophytosis (Ringworm): Effective against infections of the skin, hair, and nails caused by dermatophytes. Onychomycosis (Nail Fungus): Helps in treating fungal infections of fingernails and toenails. Tinea Infections: Treats tinea corporis, tinea cruris, and tinea pedis (athlete’s foot). Candidiasis: Useful in managing Candida infections affecting the skin and mucous membranes. Recurrent or Resistant Fungal Infections: Provides stronger antifungal action in cases not responsive to monotherapy. Benefits 1. Broad-Spectrum Antifungal Action The combination of Terbinafine and Itraconazole ensures effective activity against a wide variety of fungal species, including dermatophytes and yeasts. 2. Faster Symptom Relief By targeting fungi at multiple levels, CONARIS T100 helps relieve itching, redness, scaling, and discomfort more quickly than single-agent therapy. 3. Treats Nail and Skin Infections Terbinafine penetrates nails effectively, while Itraconazole enhances the antifungal spectrum, making the combination ideal for nail and skin fungal infections. 4. Reduces Recurrence Combination therapy decreases the risk of fungal infections returning by ensuring complete eradication of the pathogen. 5. Convenient Dosage Form Available as an oral tablet, making it easy to administer and suitable for long-term treatment if prescribed. Dosage Adults: Usually, one tablet of CONARIS T100 daily, preferably after meals, or as directed by a healthcare professional. Treatment Duration: Varies depending on the type and severity of infection; may range from 2 to 12 weeks for skin infections and longer for nail infections. Important: Do not self-adjust dosage or stop treatment prematurely, as incomplete therapy can lead to recurrence or resistance. Side Effects CONARIS T100 is generally well tolerated when used as prescribed. Mild side effects may include: Nausea or vomiting Stomach upset or diarrhea Headache Dizziness Serious Side Effects (Rare) Liver enzyme elevation (monitoring recommended for long-term use) Allergic reactions such as rash, itching, or swelling Severe gastrointestinal discomfort Consult a healthcare provider immediately if you experience jaundice, persistent fatigue, or severe allergic reactions. Precautions and Warning Pregnancy and Breastfeeding: Use only if prescribed by a doctor; safety during pregnancy is not fully established. Liver or Kidney Disorders: Dose adjustment or close monitoring may be required. Drug Interactions: Inform your doctor about all medications, especially antifungals, statins, or anticoagulants. Avoid Self-Medication: Fungal infections may mimic other skin conditions, so proper diagnosis is essential. Alcohol Consumption: Avoid alcohol as it may increase liver toxicity risk. Storage: Store in a cool, dry place away from direct sunlight and out of children’s reach. Conclusion CONARIS T100, containing Terbinafine 250 mg and Itraconazole 100 mg, is a reliable and effective treatment for a wide spectrum of fungal infections, including skin, nail, and mucosal infections. Its dual-action antifungal mechanism provides faster symptom relief, reduces recurrence, and improves overall patient outcomes. When used under medical supervision and following prescribed dosage, CONARIS T100 offers a safe and convenient option for managing both common and stubborn fungal infections, ensuring better skin and nail health and enhanced quality of life.
View Details
Terbinafine and Itraconazole Tablets 250/100 mg

INR184

CONARIS T200 is a potent antifungal combination tablet containing Terbinafine 250 mg and Itraconazole 200 mg, formulated to provide effective treatment for various fungal infections. Fungal infections of the skin, nails, and hair are common in India due to the hot and humid climate. These infections can cause itching, redness, scaling, and discomfort, affecting daily life and confidence. By combining two powerful antifungal agents, CONARIS T200 targets fungal infections effectively, providing faster relief and improved recovery compared to monotherapy. Terbinafine works by inhibiting fungal cell growth, while Itraconazole disrupts fungal cell membrane formation, resulting in a comprehensive antifungal effect. Uses CONARIS T200 is primarily prescribed for the management of: Dermatophytosis (Ringworm, Tinea Infections) Treats fungal infections affecting skin, nails, and scalp. Onychomycosis (Fungal Nail Infection) Helps in eliminating nail fungus and promotes healthy nail growth. Candidiasis (Yeast Infections) Effective against mucocutaneous and superficial candidal infections. Other Superficial Fungal Infections Useful in treating skin infections caused by dermatophytes, yeasts, and other fungi. This combination is particularly beneficial for chronic, resistant, or recurrent fungal infections. Benefits 1. Broad-Spectrum Antifungal Activity The dual action of Terbinafine and Itraconazole ensures effectiveness against a wide range of fungi, providing comprehensive treatment. 2. Faster Symptom Relief Patients experience reduced itching, redness, scaling, and discomfort sooner than with single antifungal therapy. 3. Promotes Healing Supports the restoration of healthy skin and nails, improving appearance and comfort. 4. Reduces Recurrence The combination therapy helps prevent fungal infections from returning, especially in chronic or resistant cases. 5. Convenient Oral Administration Once or twice-daily tablet dosing improves patient compliance compared to topical treatments. 6. Suitable for Adults Formulated for adult patients suffering from persistent fungal infections that require systemic therapy. Dosage The recommended dose of CONARIS T200 is usually one tablet once daily, or as directed by a physician. Duration of therapy depends on the type and severity of infection: Skin infections: Typically 2–4 weeks Nail infections: May require 6–12 weeks or longer for full recovery Important Instructions: Swallow the tablet whole with water. Take the medicine after food to reduce stomach upset. Do not skip doses and complete the full course even if symptoms improve. Always follow the prescribing doctor’s instructions to ensure optimal results. Side Effects CONARIS T200 is generally well-tolerated, but some patients may experience mild side effects: Nausea and vomiting Stomach discomfort or indigestion Headache Dizziness Serious but Rare Side Effects Liver function disturbances Allergic reactions such as rash or swelling Severe gastrointestinal discomfort If any unusual or severe symptoms appear, consult a healthcare professional immediately. Precautions and Warning Liver and Kidney Disorders: Use with caution; liver function tests may be recommended during therapy. Pregnancy and Breastfeeding: Consult your doctor before use; safety has not been fully established. Drug Interactions: Inform your doctor about other medications, particularly antacids, anticoagulants, or statins. Allergy: Avoid if allergic to Terbinafine, Itraconazole, or any other ingredient in the tablet. Alcohol Consumption: Limit alcohol intake, as it may increase the risk of liver-related side effects. Conclusion CONARIS T200 (Terbinafine 250 mg + Itraconazole 200 mg) is an effective and trusted antifungal combination for the treatment of a variety of superficial and chronic fungal infections. By targeting fungi through dual mechanisms, it provides faster relief, promotes healing, and helps prevent recurrence. With proper dosing, adherence to medical advice, and monitoring for side effects, CONARIS T200 offers a comprehensive solution for adults dealing with persistent fungal infections, helping restore healthy skin, nails, and overall comfort.
View Details
Terbinafine and Itraconazole Tablets 250/200mg

INR204

Have any question or need any business consultation?

Contact Us

Have any question or need any business consultation?

Contact Us
Chat with us